VEGFA and inflammation: Although treatment with recombinant CC10 demonstrated acute efficacy in both lamb and rabbit models by reducing lung inflammation, improving pulmonary function, and upregulating surfactant protein and vascular endothelial growth factor (VEGF) expression (Miller et al., 2005; Wolfson et al., 2008), it did not reach the primary endpoint in a recently concluded clinical trial (Davis et al., 2019).